abstract Glioblastoma Multiforme (GBM) is the most malignant and devastating primary brain tumour with a median survival of ~12-16 months. Although recent large scale sequencing projects have shed considerable light into the complexity of the disease, there remains much to be elucidated in the hopes of generating effective therapeutic strategies. Although these studies investigate the mutations and expression of bulk tumour they have limits with respect to cell of origin and the concept of brain tumour initiating cells (BTIC). Current research has challenged the old paradigm of the stochastic model as recent evidence suggests that a subset of cancer cells within a tumor is responsible for tumor initiation, maintenance, and resistance to therapy. To gain a better understanding of the different compartment of cells that GBM comprise of require careful and elegant experiments. In addition to studying GBM, exploring the role of normal neural stem cells and progenitors cells is essential to partially explain whether these GBM BTIC behave similarly or differently then their non transformed counterparts. Here we discuss the recent literature between the two models, candidate regions of glioma genesis, candidate cells of origin for GBM, and possible therapeutic avenues to explore.
Brief introduction
Conventional approaches to the treatment and management of cancer have been to eliminate all tumor cells. This approach is primarily based on the stochastic model also known as the clonal evolution model in which all tumor cells have the potential to proliferate limitlessly, self-renew and drive tumor growth [1, 2] . However, treatments tailored to this model have resulted in minimal gains towards survival post-treatment in several cancers including glioblastoma multiforme (GBM) [3] . Current research has challenged the old paradigm of the stochastic model as recent evidence suggests that a subset of cancer cells within a tumor is responsible for tumor initiation, maintenance and resistance to therapy [4, 5] . [6] . For simplicity, we will use the term tumor-initiating cells (TIC) and brain tumorinitiating cells (BTIC) to refer specifically to CNS tumor formation. Additionally, we would like to clarify that our definition does not encompass the term cell of origin. This term refers to the original cell or group of cells, which acquired neoplastic lesions to induce transformation. BTIC may be one possible candidate for the cell of origin.
BTIC have been isolated from several cancers including brain tumors such as GBM and medulloblastoma [7] [8] [9] . These isolated BTIC constitute a small fraction of the total population of tumor cells and are characterized by several hallmark features shown in Table 1 .
BTIC are able to propagate in an undifferentiated manner and are able to recapitulate the tumor when injected in low numbers (10 -10 6 in non-purified tumor cells) [7] [8] [9] [10] . BTIC express markers including CD133, nestin, and SOX2, are similar to normal neural stem cells and are isolated/derived using several means as summarized in Table 2 . In this review we will consider sources of neural stem cells and BTIC and aberrant signaling pathways within these cells. We will further discuss how targeting BTIC may provide a new strategy for therapeutic targeting and outline potential limitations and pitfalls of the cancer stem cells as therapeutic targets.
definition and sources of brain tumor initiating cells (BTiC)
The isolation of a subpopulation of stem like cells from surgical specimens of malignant gliomas lent support to the cancer stem cell hypothesis, suggesting that GBM are composed of a heterogeneous collection of cancer cells with varying tumor initiation potential [9] . [19] , resulting in the reactivation of the primitive neural epithelial marker Sox2 [19] , which is prevalently expressed in human gliomas [14] .
These results suggest that similar mechanisms might be operative in the transformation of restricted progenitors in the adult brain.
Multipotent neural progenitors are found in specialized neurogenic niches such as the 
Proliferation
The ability to produce many progeny cells, which form primarily, the bulk tumor 2. Neurosphere assays Growing tumor cells in neural basal cell medium with growth factors that enrich for neural stem cells [28, 29] . Neurospheres can be passaged numerous times and display hallmarks from Table 1 .
Adherent stem cell cultures
Growing isolated BTIC on adherent laminin-coated plates to allow for increased purity and stability, uniform growth factor delivery and reduce spontaneous differentiation [30] . 
Cell surface markers of BTIC and abberant signaling in BTIC of GBM

BTIC associated markers
BTIC share many molecular markers once thought to be exclusively attributed to NSC, such as nestin [31] , CD133 [32] , musashi-1 [33] and stage-specific mouse embryonic antigen-1 (SSEA-1) [34] , (Table 3) . Unfortunately, at this time no cell marker is absolute in identifying BTIC. However, two cell surface markers, nestin and CD133 (prominin-1), have been of particular interest in the study of brain tumor organization. It has been observed that these markers are associated with grade of malignancy and are likely prognostic markers for brain tumor patients [35, 36] .
The intermediate filament nestin is expressed in all CNS lineages restricted progenitors and in astrocytes [37] . Evidence suggests that nestin expression is highly correlated with "stemness", whereby NSC progeny, which takes on a more committed role, results in a downregulation of nestin expression followed by upregulation of more committed neuronal and astrocytic markers [38] . Expression of nestin has been reported in BTIC, however its expression is variable and non-specific for BTIC [31] .
The neuronal stem cell marker CD133 (prominin-1 in mice) has received particular interest as its expression has been associated with both, tumor initiation capacity and radioresistance [9, 39] . Initial reports indicated that as few as 100 CD133+ cells collected from GBM surgical specimens, could form xenograft tumors in immunocompromised mice, that penetrance, only when targeted to neural precursors cells but not differentiated glia [23] .
Better mouse models investigating the role of the SVZ as a region of glioma generating potential will be essential to address these critical questions [24] . [25] . MADM mouse transgenics and current BRAINBOW mouse models will allow for efficient labeling and lineage tracing that will allow for a better method of identifying candidate cells of origin in brain tumors such as GBM [25, 26] . However translation of these results into humans may not be as easy. For recapitulated the phenotype of the tumor from which they were isolated [9] . This is in sharp contrast to the 10 6 CD133-cells required for the same phenotype [9] . Although there has been overwhelming evidence that supports and multilineage differentiation potential [34] .
However further validation that will identify SSEA-1 as a specific marker of BTIC is still pending.
As inferred above, neither of the makers by themselves seem to be specific for BTIC, it is possible that similar to hematopoietic stem cells, which are probably the most thoroughly characterized population, a combination of markers will ultimately best define BTIC.
Aberrant signaling pathways associated with BTIC
Multiple signaling pathways have been implicated to be disrupted in BTIC, interestingly they include those which serve to regulate the self-renewal, proliferation, and survival properties of normal stem cells. This include the hedgehog family of regulatory pathways which mediate the proliferation of progenitor cells through the activations of the transcription factor Gli, which promote cell cycle entry and DNA repair [42] . In the adult central nervous system, Gli1 is expressed by neural progenitors in germinal regions such as the SVZ and the dentate gyrus, were it is thought to play a role in the maintenance of this stem cell population [43] . Like the hedgehog pathway, the Recent studies have reported its expression as a result of environmental stress, questioning its validity as a BTIC marker.
Nestin
Expressed in all CNS lineage restricted progenitors astrocytes and BTIC. However, the expression of this marker is variable an non-specific to BTIC.
3. Musashi-1 Expressed in normal NSC and BTIC. Its expression has been correlated with tumor grade and proliferative activity. Its role as a BTIC specific marker its non-conclusive.
4. SSEA-1 A neural stem progenitor marker shown to be express in GBM cells that fulfill the functional criteria of BTIC. Proposed to be a better BTIC marker in combination with CD133. Table 3 . Markers of BTIC.
Translational Neuroscience to their non-BTIC counterparts [33] . Therefore, targeted therapies to Chk1/2 may be an effective strategy to overcome radioresistance.
In addition to radioresistance, elevated levels of drug transporters ABCG2 and ABCA3 have been shown to promote temozolomide resistance in BTIC [53, 54] .
A novel approach for targeting BTIC may be promoting differentiation of these cells to limit their replication and self-renewal properties.
Upregulation of bone morphogenic proteins (BMP) such as BMP4 has been shown to induce differentiation of BTIC, limit their self-renewal ability and drastically reduce proliferation [55] .
The vascular niche that promotes and allows BTIC to grow has also become a potential target.
Use of the anti VEGF antibody, bevacizumab has been shown to reduce the CD133+ BTIC population in vitro and in vivo illustrating that disruption of the BTIC niche may be an effective therapeutic strategy [56, 57] 
Conclusion
The concept of BTIC and CSC provide a new therapeutic target for effective treatment. 
